Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Thierry

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 22, 2009
Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimusA Servais, V Meas-Yedid, O Toupance, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 19, 2016
Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 GenotypeN Pallet, I Etienne, M Buchler, et al.
Journal of Transplantation|May 16, 2014
Three-year outcomes in kidney transplant patients randomized to steroid-free immunosuppression or steroid withdrawal, with enteric-coated mycophenolate sodium and cyclosporine: the infinity studyA Thierry, G Mourad, M Büchler, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 3, 2007
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantationY Le Meur, M Büchler, A Thierry, et al.
Trials|June 23, 2019
PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled studyE Gaiffe, T Crepin, J Bamoulid, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 16, 2015
Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrationsN Pallet, A-S Jannot, M El Bahri, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 7, 2016
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic ScreeningC Damon, M Luck, L Toullec, et al.
Nature|June 2, 1994
Complete DNA sequence of yeast chromosome XIB Dujon, D Alexandraki, B André, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 22, 2009
Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimusA Servais, V Meas-Yedid, O Toupance, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 19, 2016
Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 GenotypeN Pallet, I Etienne, M Buchler, et al.
Journal of Transplantation|May 16, 2014
Three-year outcomes in kidney transplant patients randomized to steroid-free immunosuppression or steroid withdrawal, with enteric-coated mycophenolate sodium and cyclosporine: the infinity studyA Thierry, G Mourad, M Büchler, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 3, 2007
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantationY Le Meur, M Büchler, A Thierry, et al.
Trials|June 23, 2019
PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled studyE Gaiffe, T Crepin, J Bamoulid, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 16, 2015
Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrationsN Pallet, A-S Jannot, M El Bahri, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 7, 2016
Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic ScreeningC Damon, M Luck, L Toullec, et al.
Nature|June 2, 1994
Complete DNA sequence of yeast chromosome XIB Dujon, D Alexandraki, B André, et al.
Pageof 10